Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study.

Savage, Laura; Goodfield, Mark; Horton, Laura; Watad, Abdulla; Hensor, Elizabeth; Emery, Paul; Wakefield, Richard; Wittmann, Miriam; McGonagle, Dennis

Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study.

Savage, Laura; Goodfield, Mark; Horton, Laura; Watad, Abdulla; Hensor, Elizabeth; Emery, Paul; Wakefield, Richard; Wittmann, Miriam; McGonagle, Dennis.

Afiliação

Savage L; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Goodfield M; Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Horton L; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Watad A; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Sheba Medical Center, Ramat-Gan, Israel, and Tel-Aviv University, Tel-Aviv, Israel.
Hensor E; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Emery P; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Wakefield R; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Wittmann M; Leeds Teaching Hospitals NHS Trust, Leeds, UK, and University of Bradford, Bradford, UK.
McGonagle D; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Arthritis Rheumatol ; 71(4): 626-631, 2019 04.

Article em En | MEDLINE | ID: mdl-30468001

Assuntos

Fármacos Dermatológicos/uso terapêutico; Entesopatia/diagnóstico por imagem; Psoríase/tratamento farmacológico; Ustekinumab/uso terapêutico; Adulto; Idoso; Doença Crônica; Entesopatia/etiologia; Entesopatia/patologia; Estudos de Viabilidade; Feminino; Humanos; Inflamação; Masculino; Pessoa de Meia-Idade; Estudos Prospectivos; Psoríase/complicações; Psoríase/diagnóstico por imagem; Índice de Gravidade de Doença; Resultado do Tratamento; Ultrassonografia; Adulto Jovem

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Fármacos Dermatológicos / Ustekinumab / Entesopatia Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google